ArticleCancer immunology research2023
CD8+ T cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance.
Article in Cancer immunology research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 19 citations in OpenAlex.
- Optimizing first-line therapy for double-expressor lymphoma: a systematic review and meta-analysis of novel agent-augmented R-CHOP regimens.Cancer cell international · 2026Review
- Targeting senescence-like tumor-associated macrophages sensitizes chemotherapy in triple-negative breast cancer.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- SMPD1 as a Potential Prognostic Biomarker in Glioma Is Associated With an Immunosuppressive Microenvironment.CNS neuroscience & therapeutics · 2026Article
- C-type lectin-like domain family 2 (CLEC2D) promotes proliferation and migration of breast cancer and serves as a poor prognostic factor.Breast cancer (Tokyo, Japan) · 2026Article
- CD161 serves as a prognostic biomarker and predicts immunotherapy response in head and neck squamous cell carcinoma.Frontiers in immunology · 2026Article
- Research hotspots and frontiers in the tumor microenvironment of gastric cancer: a bibliometric review from 2005 to 2024.Translational cancer research · 2025Article
- Review
- An orally administered gene editing nanoparticle boosts chemo-immunotherapy in colorectal cancer.Nature nanotechnology · 2025Article
- The Emerging Role of CD8Cancers · 2025Review
- Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer.Cancer research · 2025Article
- CD161, a promising prognostic biomarker in hepatocellular carcinoma, correlates with immune infiltration.PeerJ · 2025Article
- Pterostilbene inhibits non-small cell lung cancer progression by activating the STING pathway and enhancing antitumor immune response.Frontiers in immunology · 2025Article
- ASM is a therapeutic target in dermatomyositis by regulating the differentiation of naive CD4 + T cells into Th17 and Treg subsets.Skeletal muscle · 2024Article
- Article
- Poor clinical outcomes and immunoevasive contexture in CD161Journal for immunotherapy of cancer · 2024Article
- CD161Oncoimmunology · 2024Article
- Article
- The colibactin-producingGut microbesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic efficacy of chemotherapy is in part a result of its ability to enhance adaptive antitumor immune responses. However, tumor cells exploit various evasion mechanisms to escape the immune attack and blunt chemosensitivity. Herein, we report that through single-cell profiling of the tumor immune microenvironment, we identified a subset of CD161-overexpressing CD8+ T cells enriched in chemoresistant tumors. CD161 engagement repressed the calcium influx and cytolytic capacity of CD8+ T cells through acid sphingomyelinase activation and ceramide generation. Targeting CD161 in adoptively transferred cytotoxic T lymphocytes enhanced antitumor immunity and reversed chemoresistance in patient-derived xenografts in vivo. Clinically, CD161 expression on CD8+ T cells was associated with chemoresistance and shortened patient survival. Our findings provide insights into novel immunosuppressive mechanisms in chemoresistance and highlight targeting CD161 as a potential therapeutic strategy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.